Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma

Bruton tyrosine kinase (BTK) inhibitor ibrutinib has been validated as an effective drug to treat B cell malignancies. Combined therapies comprising ibrutinib and anti-CD20 antibodies like rituximab were designed as a backbone in many clinical trials. However, the off-target inhibition of ibrutinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Hui, Wang, Xing, Li, Jiao, Ye, Yingying, Wang, Dedao, Fang, Wei, Mi, Lan, Ding, Ning, Wang, Xiaogan, Song, Yuqin, Zhu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082047/
https://www.ncbi.nlm.nih.gov/pubmed/33981831
http://dx.doi.org/10.1016/j.omto.2021.03.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082047/
https://www.ncbi.nlm.nih.gov/pubmed/33981831
http://dx.doi.org/10.1016/j.omto.2021.03.015

Ejemplares similares